COMP <GO>
EWTX vs INDV // GROSS PROFIT MARGIN
Edgewise Therapeutics Inc. (NASDAQ) VS. Indivior Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: EWTX 2
— INDV 9
■ METRIC PARITY
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
gross-margins
—
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
gross-margins
80.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. INDV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | INDV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 80.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | 62.20% | -94.10 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 13.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | -2.24% | -1.17 | INDV | /fcf-yield <GO> |
| Operating Margin | -16.20% | 21.10% | -37.30 | INDV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 16.90% | -16.90 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 4.30% | -5.40 | INDV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.13 | +22.87 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | INDV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 52.3 | -6.60 | INDV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 18.4x | +6.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $4.17B | $49.8M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | INDV REV | EWTX GROSS % | INDV GROSS % | EWTX FCF | INDV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $535.9M | $1.24B | — | 80.2% | -$144.1M | -$93.0M |
| FY 2024 | $444.7M | $1.19B | — | 80.6% | -$110.3M | $7.0M |
| FY 2023 | $320.2M | $1.09B | — | — | -$91.9M | -$349.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
INDV // BETA 1.15